Recombinant Human FIGF Protein，His

FIGF (FMS-like tyrosine kinase 4-induced gene) is an important protein implicated in various physiological processes, particularly in angiogenesis and lymphangiogenesis. Identified primarily for its roles in the development of blood and lymphatic vessels, FIGF acts as a ligand for receptor kinases such as VEGFR-3 and VEGFR-2, activating downstream signaling pathways that promote endothelial cell proliferation and migration. Research into the recombinant expression of FIGF has gained traction due to its potential therapeutic applications in treating diseases characterized by pathological angiogenesis, such as cancer and age-related macular degeneration. Additionally, understanding the precise molecular mechanisms of FIGF can provide insights into cardiovascular and lymphatic system disorders. The generation of FIGF recombinant proteins allows for the exploration of its biological functions and interactions, which are crucial for advancing knowledge in vascular biology and developing novel therapeutic strategies. Enhanced production techniques, such as the use of engineered expression systems, have enabled researchers to obtain higher yields of active FIGF, facilitating detailed functional assays and structural studies. This growing body of work aims to leverage FIGF's biological properties for innovative therapeutic applications, aiming to harness its angiogenic potential while minimizing adverse effects. Thus, ongoing research into FIGF recombinant proteins is vital for uncovering new avenues for drug development and understanding the intricate networks regulating vascular health.